Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
5.439
Zitationen
13
Autoren
2010
Jahr
Abstract
The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer. No effect on the time to disease progression was observed. (Funded by Dendreon; ClinicalTrials.gov number, NCT00065442.)
Ähnliche Arbeiten
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 · 30.895 Zit.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
2010 · 15.003 Zit.
Dendritic cells and the control of immunity
1998 · 14.269 Zit.
Prospective identification of tumorigenic breast cancer cells
2003 · 10.319 Zit.
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
2012 · 7.924 Zit.
Autoren
Institutionen
- Dana-Farber Cancer Institute(US)
- Dana-Farber/Harvard Cancer Center(US)
- Harvard University(US)
- University of Washington(US)
- Seattle Cancer Care Alliance(US)
- Carolina Urologic Research Center(US)
- University of California, San Francisco(US)
- Vanderbilt University Medical Center(US)
- Sharp HealthCare Foundation(US)
- NYU Langone Health(US)
- Cleveland Clinic(US)
- Dendreon (United States)(US)
- Eastern Virginia Medical School(US)